Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.69 |
| ▸ | NPC1 | O15118 | 7/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL417902 | 0.96 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL417903 | 0.96 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL565748 | 0.96 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL29051144 | 0.91 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL29051150 | 0.91 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2443725 | 0.91 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL8472269 | 0.87 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3019067 | 0.87 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2453027 | 0.87 | RAB9A (0.53) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2449725 | 0.83 | RAB9A (0.50) | RAB9ANPC1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586609-B2 | Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-11-19 | — | — | US | disclosed |
| US-20100298378-A1 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-11-25 | — | — | US | disclosed |
| US-7838547-B2 | Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| CN-101006091-B | Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament | SANOFI AVENTIS DEUTSCHLAND | 2010-09-15 | — | — | CN | disclosed |
| US-20070299077-A1 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-12-27 | — | — | US | disclosed |
| CN-101006091-A | Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-07-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299077-A1 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | PAH, NAT1, AADAT | RAB9A 3902/4885NPC1 814/4885SMN1; SMN2 3283/4885 |
| US-20100298378-A1 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | PAH, NAT1, AADAT | RAB9A 3902/4885NPC1 814/4885SMN1; SMN2 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.